高劑量艾普拉唑聯(lián)合阿莫西林用于老年新發(fā)幽門螺桿菌感染患者的臨床研究

打開文本圖片集

中圖分類號R975 文獻(xiàn)標(biāo)志碼A 文章編號 1001-0408（2025）14-1792-05

DOI 10.6039/j.issn.1001-0408.2025.14.18

ABSTRACTOBJECTIVEToevaluatetheeficacyandsafetyof high-doseilaprazolecombinedwithamoxiclinfornewly diagnosedelderlypatientswithHelicobacterpylori（Hp）infection，ndanalyzeindependentriskfactorsforfailureofHpinfection eradication treatmentMETHODSTotally2Ocasesof newlydiagnosedelderlypatientswithHpinfectioninXinxiangCentral Hospital fromAugust1，2021toDecember1，2024 wereselectedandrandomlydivided intocontrolgroupandstudygroup，with 100cases ineachgroup.Thecontrol groupwas treatedwithclasicquadrupletherapyregimen（Amoxicillncapsules+ Clarithromycintablets+Bismuthpotassumcitratetablets+Ilprazoleenteric-coatedtablets）.Thestudygroupwastreatedwithhig doseIaprazoleenteric-coatedtablets+Amoxicilincapsules.Allpatientsereadministeredmedicationforweeks.Hperadication ratesintetwogroups werecomparedusing intention-to-treat（ITT）and per-protocol（PP）analyses.Theincidenceof adverse reactionsinbothgroupswasalsorecorded.Themultiple-factorLogisticregressonanalysiswasusedtoidentifyindependentrisk factors for failure of Hp infectioneradication treatment.RESULTSIn ITT andPPanalyses，therewas no significant differenceof Hp eradication rates between the two groups P>0.05 ）.There was no significant difference in incidence of mild to moderate adverse reactions between the two groups （ ?P>0.05 ）.BMI ?18.5kg/m2 BMI>23.9kg/m2 ，rural residence，concomitant diabetes andconcomitant heart diseasewereidentified asindependent risk factors influencing the failure of Hp infection eradication treatment （ （P<0.05 ）. CONCLUSIONS The eficacy and safety of high-dose ilaprazole combined with amoxicilin are comparable to classic quadruple therapy regimen in treating newly diagnosed elderly patients with Hp infection. Independent risk factors influencing the failure of Hp infection eradication treatment include BMI ?18.5kg/m2 ，BMI >23.9kg/m2 ，rural residence， concomitant diabetesand concomitant heart disease.

KEYWORDS Helicobacter pylori；high-dose dual therapy; ilaprazole；amoxicillin；intention-to-treat；per-protocol；elderly patient

幽門螺桿菌Helicobacterpylori（簡稱"Hp"）是一種主要存在于人體胃部及十二指腸內(nèi)的革蘭氏陰性菌。（剩余10047字）